Recent Updates
Recently added Catalysts

SFP

Phase 3

End Stage Renal Disease | Small molecule | Nephrology |Rockwell Medical, Inc.|Last Updated: Oct 25, 2016

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment718
FDA Designations
No designations recorded
Clinical trial landscape

SFP · 1 trial · 2 indications

Phase 3 1
NCT01503021Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic HemodialysisEnd Stage Renal Disease
COMPLETED718 Analytics
PHASE3COMPLETED
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis
End Stage Renal DiseaseUnlock trial analytics
Study Endpoints
Primary Endpoints
Incidence of Treatment-emergent Adverse Events
Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study

Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention.

Incidence of Treatment-emergent Adverse Events of Intradialytic Hypotension
Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study

Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met the protocol criteria for intradialytic hypotension. Intradialytic hypotension events were only to have been reported as adverse events if they exceeded the individual subject's baseline pattern of intradialytic hypotension.

Incidence of Related Suspected Hypersensitivity Reactions
Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study

Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met protocol criteria for suspected hypersensitivity reactions.

Secondary Endpoints
Incidence of Composite Cardiovascular Events
Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study
Incidence of Hemodialysis Vascular Access Thrombotic Events
Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study
Incidence of Other Thrombotic Events
Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
SFP/PlaceboOTHERSoluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks, then 1 week washout, then standard liquid bicarbonate concentrate without SFP x 2 weeks
Placebo/SFPOTHERStandard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks.
Interventions
NameTypeDescription
SFPDRUGDialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
PlaceboOTHERDialysis with standard liquid bicarbonate concentrate without iron
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites31

Parent Study, Double Blinded, Crossover: Key Inclusion Criteria: 1. Adult ≥ 18 years of age. 2. Has chronic kidney disease (CKD) receiving maintenance hemodialysis (HD) (CKD-HD subjects) and regularly undergoing 2 or more dialysis sessions per week. 3. Stable pre-dialysis Hgb ≥ 9.0 to ≤ 12.5 g/dL....

Countries:United StatesCanada
Unlock Eligibility Criteria